S-1: Hyperliquid Strategies Secures $1 Billion Equity Facility

Sentiment:

Registration Statement 22 October 2025 5:14 PM

📋All filings for Hyperliquid Strategies INC

Hyperliquid Strategies Inc. has entered into a $1.0 billion committed equity facility with Chardan Capital Markets LLC, enabling future stock sales to fund its HYPE token treasury strategy following a business combination.

Delay expectedThe New Life Agreement for SON-080 was subject to a 'Give Back Option' by New Life, indicating a potential delay or change in the development path for that asset.The 'Outside Date' for the Business Combination may be extended by either party for up to 60 days if the SEC has not declared a registration statement effective.The commencement of the vesting schedule in November 2025 for HYPE tokens allocated to core contributors could pressure HYPE token prices in the near term, which could be seen as a delay in full market stability or liquidity.

Capital raiseCommitted Equity Facility (ChEF) with Chardan Capital Markets LLC for up to $1,000,000,000 in aggregate gross purchase price of common stock.Initial PIPE financing raised $5.5 million through Series 5 Preferred Stock and Initial PIPE Warrants.Bridge Financing of $2.0 million in convertible notes.Closing PIPE expects to raise $305 million in gross proceeds from the sale of Company Common Stock.Pubco intends to fund further HYPE token acquisitions primarily through issuances of common stock and a variety of fixed-income instruments, including debt, convertible notes, and preferred stock.Pubco may enter into additional capital raising transactions collateralized by its HYPE holdings.

Summary

Hyperliquid Strategies Inc. (Pubco) entered into a ChEF Purchase Agreement with Chardan Capital Markets LLC (Investor) on October 22, 2025, allowing Pubco to sell up to $1,000,000,000 in common stock at its discretion over a 36-month period.
Shares will be sold at a discount to the Volume Weighted Average Price (VWAP): 2.5% for VWAP/Intraday VWAP Purchases and 5.0% for Off-Hour VWAP Purchases.
Pubco will pay Chardan a non-refundable commitment fee totaling $1,000,000, structured in three tranches: $125,000 at Commencement Date, $250,000 at $25M proceeds, and $625,000 at $50M proceeds, plus a $25,000 documentation fee.
Pubco will reimburse Chardan's legal fees up to $125,000 initially, and up to $25,000 per fiscal quarter for ongoing diligence.
The offering is conditioned upon the closing of a Business Combination involving Sonnet BioTherapeutics Holdings, Inc. and Rorschach I LLC.
Post-Business Combination, Pubco will pursue a HYPE token treasury strategy, aiming to accumulate HYPE tokens using proceeds from the facility and other capital raises.
Pubco expects to acquire no less than $265 million worth of HYPE tokens from the initial $304.7 million cash proceeds from the Closing PIPE, in addition to 12.6 million HYPE tokens contributed by Rorschach.
Pubco plans to stake substantially all of its HYPE token holdings to generate income, with rewards expected to be reinvested.
The total number of shares registered for resale by Chardan is up to 160,000,000.
Chardan is prohibited from short-selling or hedging the Common Stock to establish a net short position during the agreement term.

Sentiment

Score: 6

Explanation: The filing details a substantial committed equity facility and a clear strategic direction towards digital asset treasury management, which could be transformative. However, this is balanced by the inherent high volatility and regulatory uncertainty of digital assets, Sonnet's ongoing financial challenges, and the significant dilution risk for existing shareholders.

Positives

Secured a significant $1.0 billion committed equity facility, providing substantial potential capital for future operations.
The facility offers flexibility for Hyperliquid Strategies Inc. to draw capital at its discretion based on market conditions.
The company plans a clear HYPE token treasury strategy, including accumulation and staking for income generation, positioning itself as a differentiated public market vehicle for exposure to the Hyperliquid ecosystem.
The business combination is expected to result in Pubco holding approximately $583 million in HYPE tokens and at least $305 million in cash on its balance sheet at closing.
A new management team and board members with extensive experience in finance, investment management, and digital assets are expected post-transaction.
Sonnet's biotech assets, including lead candidate SON-1010, will continue development as a wholly-owned subsidiary, with dedicated funding.

Negatives

Significant dilution risk for existing stockholders due to the issuance of up to 160,000,000 shares under the facility and other transaction-related equity.
The actual proceeds from the equity facility are uncertain and depend on market prices and the company's discretion to sell.
HYPE tokens are highly volatile assets, introducing significant risk to the company's treasury strategy and stock price.
The digital asset regulatory landscape is uncertain and evolving, potentially impacting HYPE token value and company operations.
Sonnet has a history of significant operating losses and requires substantial additional funding, raising going concern doubts.
The integration of Sonnet and Rorschach businesses poses risks and requires substantial management resources.
The CVRs for Sonnet stockholders are subject to significant deductions and uncertainties, with no assurance of payment.
The company will incur increased costs as a public company.

Risks

It is not possible to predict the actual number of shares sold under the Purchase Agreement, gross proceeds, or dilution.
Investors buying Common Stock from Chardan at different times may pay different prices and experience varying dilution.
Sales or issuance of shares to Chardan, or the perception of such sales, could decrease the stock price.
Proceeds from sales may be used in ways investors disagree with or that do not yield significant returns.
HYPE is a highly volatile asset, and price fluctuations may influence financial results and stock price.
HYPE and other digital assets are subject to significant legal and regulatory uncertainty, potentially impacting their price and the company's ability to own/transfer them.
The HYPE treasury strategy subjects the company to enhanced regulatory oversight.
Using capital to acquire HYPE may adversely affect financial results and stock price.
Risk of being deemed an investment company under the Investment Company Act, which would impose impractical restrictions.
Disruption or unanticipated difficulties in the Hyperliquid network could negatively impact HYPE value.
Risks relating to the custody of HYPE, including loss/destruction of private keys, cyberattacks, and smart contract vulnerabilities.
Historical financial statements do not reflect future earnings variability from HYPE holdings.
Unrealized fair value gains on HYPE holdings could trigger the corporate alternative minimum tax.
HYPE trading venues may experience fraud, security failures, or operational problems due to unregulated nature and lack of transparency.
Concentration of HYPE holdings enhances inherent risks.
Emergence or growth of other blockchains/digital assets could negatively impact HYPE price.
Commencement of vesting of a large number of HYPE tokens in November 2025 may cause increased price volatility and downward pressure.
Competition from central bank digital currencies and emerging payments initiatives could adversely affect HYPE price.
HYPE holdings will be less liquid than cash and may not serve as a source of liquidity to the same extent.
Risks associated with staking HYPE, including liquidity risks, validator-related risks, market/economic risks, regulatory/tax risks, and technological/operational risks.
Risks associated with serving as a validator, including operational, financial, technical, security, regulatory, tax, market, and economic risks.
Broad discretion in the use of PIPE financing proceeds.
Completion of Transactions may trigger change in control provisions in existing agreements.
Transactions involve substantial costs and management resources.
Pubco stockholders will experience dilution from various equity issuances.
Litigation relating to Transactions could result in injunctions or substantial costs.
Inability to successfully integrate Sonnet and Rorschach businesses or realize anticipated benefits.
Disruption and uncertainty for employees due to Transactions.
Trading price and volume of Pubco may be volatile.
Unaudited pro forma financial statements are based on preliminary estimates and assumptions, actual results may differ.
Pubco will incur increased costs as a public company and management will devote substantial time to compliance.
Operating results may fluctuate significantly or fall below expectations.
Pubco is not subject to legal/regulatory obligations of investment companies.
Security breach or cyberattack could result in loss of HYPE.
Sonnet has a history of significant operating losses and expects increasing losses.
Sonnet needs substantial additional funding and may be forced to delay/reduce programs.
Sonnet's limited operating history makes future viability assessment difficult.
Sonnet's product candidates are early stage and represent a new category, subject to heightened regulatory scrutiny.
Sonnet's product candidates need to undergo time-consuming, expensive, and unpredictable preclinical/clinical trials with high failure risk.
Difficulty enrolling patients in clinical trials could cause delays.
Results of preclinical/early clinical trials may not predict future success.
Product candidates may cause undesirable side effects.
Failure to identify or discover additional product candidates.
Expending limited resources on less profitable/successful product candidates.
Potential product liability claims.
Inability to obtain or realize benefits from FDA designations (Fast Track, Breakthrough Therapy, Priority Review).
Obtaining marketing approval in one jurisdiction does not guarantee approval in others.
Widespread outbreak of communicable diseases could adversely affect business.
Dependence on third-party collaborators for development/commercialization.
Conflicts with collaborators/licensors.
Reliance on third parties for clinical trials and manufacturing.
Reliance on third parties requires sharing trade secrets, increasing risk of discovery/misappropriation.
Inability to obtain/maintain patent and IP protection, or insufficient scope.
Issued patents could be found invalid/unenforceable.
Claims challenging inventorship/ownership of IP.
Non-compliance with patent agency requirements could reduce/eliminate patent protection.
Failure to obtain patent term extension/data exclusivity.
Changes in patent law could diminish patent value.
Litigation for infringing third-party IP rights.
Claims of misappropriating confidential information/trade secrets.
Involvement in lawsuits to protect/enforce IP rights.
Failure to comply with future IP licenses.
Inadequate protection of trademarks/trade names.
Limited number of employees and ability to retain key personnel.
Employee/contractor misconduct.
Difficulties in managing growth.
Market price of Company Common Stock may be volatile.
Failure to satisfy Nasdaq listing requirements.
Pubco management may use proceeds in ways stockholders disagree with.
Pubco may use proceeds to purchase HYPE, which is highly volatile.
Pubco is not subject to legal/regulatory obligations of investment companies.
Security breach or cyberattack could result in loss of HYPE.
Sonnet stockholders will experience significant ownership/voting power dilution.
Intended benefits of Transactions may not be realized.
Sonnet and Rorschach expected to incur substantial expenses related to Transactions.
Sonnet or Rorschach may waive Closing conditions without re-soliciting stockholder approval.
Future sales and issuances of Pubco Common Stock could result in dilution.
Sales of substantial number of shares by stockholders could cause price to fall.
Failure to comply with Nasdaq listing standards.
Pubco's operating results may fluctuate significantly.
If equity research analysts do not publish favorable reports, stock price could decline.
Cyber-attacks or failures in IT systems.
Company Common Stock could be further diluted by additional issuances.
Shares eligible for future sale may adversely affect the market.

Future Outlook

Hyperliquid Strategies Inc. intends to use net proceeds from its committed equity facility and other capital raises for general corporate purposes, primarily focusing on accumulating and staking HYPE tokens to support the Hyperliquid ecosystem's long-term growth and generate income. Sonnet, as a wholly-owned subsidiary, will continue developing its biotech assets, with key clinical trial data expected in H2 calendar year 2025. Pubco plans a phased strategic execution over the next 12+ months, emphasizing HYPE accumulation, staking optimization, and opportunistic M&A within the digital asset space.

Management Comments

We believe our FHAB technology... is a distinguishing feature of our biopharmaceutical platform that is well suited for future drug development across a range of human disease areas, including oncology, autoimmune, pathogenic, inflammatory, and hematological conditions.
We believe our FHAB integrated IL-12 is tumor-targeted with an enhanced PK profile that differentiates it from the competition.
We anticipate using a dose of SON-080 that is 50-fold less than the prior IL-6 MTD and expect a more benign adverse event profile going forward.
We believe that SON-080 has significant potential for treating other neuropathies, including DPN, as well as other diseases of the nervous system, and we are currently evaluating forward development paths for these opportunities.
Our goal is to rapidly advance our pipeline and leverage our therapeutic FHAB platform to become a leader in the discovery, development, and commercialization of biologic drugs.
Pubco's primary strategic objective is to benefit from and support the long-term growth and adoption of the Hyperliquid ecosystem.
Pubco views its HYPE token holdings as long-term holdings and expects to continue to accumulate HYPE in the future.
Pubco believes that this strategy positions it as a differentiated public market vehicle for investors seeking exposure to the Hyperliquid ecosystem, through its direct HYPE token ownership, its active deployment of HYPE tokens to generate additional income and through its alignment with and support of the Hyperliquid ecosystem.

Industry Context

The filing highlights the highly competitive nature of the life sciences industry, particularly in oncology and biopharmaceutical development, with numerous large pharmaceutical and biotechnology companies as competitors. It also delves into the nascent and volatile digital asset market, emphasizing the significant legal and regulatory uncertainty surrounding cryptocurrencies like HYPE tokens. The company's HYPE treasury strategy positions it within the emerging trend of public companies holding digital assets, a strategy that is subject to intense scrutiny and evolving accounting standards (ASU 2023-08). The focus on decentralized finance (DeFi) and Layer-1 blockchains like Hyperliquid places the company at the forefront of a rapidly developing, yet unregulated, financial technology sector.

Comparison to Industry Standards

Sonnet's FHAB technology is presented as a distinguishing feature, aiming to improve drug accumulation in tumors and extend activity duration, differentiating it from conventional cytokine therapies.
SON-080's target dose is 50-fold less than prior IL-6 MTD, suggesting a potentially more benign adverse event profile compared to previous IL-6 clinical evaluations.
The Hyperliquid protocol's average daily market share of Perps trading volume on all decentralized exchanges was 61% during August 2025, indicating a leading position in its specific niche within the DeFi sector.
HYPE token is among the top 12 cryptocurrencies by market capitalization, but faces competition from established digital assets like Bitcoin and Ether, and other smart contract platforms (Ethereum, Solana, Polkadot, Avalanche, Cardano).
The company's HYPE treasury strategy aims to reflect the largest HYPE token holdings by a U.S. public company.
The staking reward model for HYPE is explicitly stated to be 'modeled after Ethereum,' providing a direct comparison to an industry standard.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Executive Officer	NA	David Schamis	Post-Transactions	New appointment following Business Combination
Chief Financial Officer	NA	Brett Beldner	Post-Transactions	New appointment following Business Combination
Chief Operating Officer	NA	Jeroen Nieuwkoop	Post-Transactions	New appointment following Business Combination
Chairman of the Board	NA	Bob Diamond	Post-Transactions	New appointment following Business Combination
Director	NA	Jeff Tuder	Post-Transactions	New appointment following Business Combination
Director	NA	Eric S. Rosengren	Post-Transactions	New appointment following Business Combination
Director	NA	Thomas C. King	Post-Transactions	New appointment following Business Combination
Director	NA	Larry Leibowitz	Post-Transactions	New appointment following Business Combination
Chief Executive Officer (Sonnet Subsidiary)	Pankaj Mohan, Ph.D. (Sonnet)	Raghu Rao	Post-Transactions	Will remain CEO of Sonnet, operating as a wholly-owned subsidiary of Pubco
Chief Executive Officer (Sonnet)	Pankaj Mohan, Ph.D.	Raghu Rao (Interim)	2025-04-01	Replacement
Chief Financial Officer (Sonnet)	Jay Cross	Donald Griffith	2025-02-12	Replacement
Chief Business Officer (Sonnet)	NA	Dr. Stephen McAndrew	2025-02-12	New appointment

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Composition	Pubco Board will initially comprise seven members, including Robert Diamond as Chairman, Jeff Tuder, Eric Rosengren, Thomas King, Larry Leibowitz, Nailesh Bhatt, and Albert Dyrness.	Post-Transactions	Establishes new leadership and strategic direction for the combined entity.
Special Meetings of Stockholders	Pubco's A&R Organizational Documents specify that special meetings of stockholders may be called only by the chairman of the board, the chief executive officer, and the directors entitled to cast a majority of the votes of Pubco Board.	Post-Transactions	Restricts the ability of individual stockholders to call special meetings, centralizing control with management and the board.
Staggered Board	Pubco's A&R Organizational Documents provide for a staggered board of directors divided into three classes with each class serving staggered three-year terms.	Post-Transactions	Makes it more difficult for stockholders to replace a majority of the board in a single election, potentially deterring hostile takeovers.
Preferred Stock Authorization	Pubco's A&R Organizational Documents authorize the board to create and issue additional series of preferred stock without stockholder approval.	Post-Transactions	Provides the board with flexibility to raise capital or implement anti-takeover measures, potentially diluting voting power or rights of common stockholders.
Stockholder Action by Written Consent	Pubco's A&R Organizational Documents prohibit stockholder action by written consent.	Post-Transactions	Requires all stockholder actions to occur at duly constituted meetings, potentially slowing down stockholder-initiated changes.
Advance Notice Requirements	Pubco's A&R Organizational Documents establish advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on by stockholders at stockholders meetings.	Post-Transactions	Ensures orderly meetings and provides the board time to consider proposals, but can also deter last-minute challenges to management or board nominees.
Delaware General Corporation Law (DGCL) Section 203	Pubco is subject to the provisions of Section 203 of the DGCL regulating corporate takeovers, which prohibits business combinations with interested stockholders (15% or more ownership) for three years unless certain conditions are met.	Post-Transactions	Provides a defense against hostile takeovers by limiting the ability of large shareholders to effect business combinations without board approval.
Committee Structure	Pubco will have an Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee, with members qualifying as independent under Nasdaq and SEC rules.	Post-Transactions	Establishes standard public company governance structures to ensure oversight and compliance.
Indemnification of Directors and Officers	Pubco Charter provides for indemnification of directors and officers to the fullest extent permitted by DGCL.	Post-Transactions	Protects directors and officers from liabilities arising from their service, potentially encouraging qualified individuals to serve.

Legal Proceedings

Litigation relating to the Transactions could result in an injunction preventing completion of the Transactions, substantial costs to Sonnet and/or may adversely affect Sonnet's business, financial condition or results of operations following the Transactions.
Securities class action lawsuits and derivative lawsuits are often brought against public companies that have entered into acquisition, merger or other business combination agreements.
The defense or settlement of any lawsuit or claim that remains unresolved at the time the merger is completed may adversely affect Sonnet's business, financial condition, results of operations and cash flows.
We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws health information privacy and security laws, and other health care laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
Law enforcement authorities are increasingly focused on enforcing fraud and abuse laws, and it is possible that some of our practices may be challenged under these laws.
We may be subject to claims challenging the inventorship or ownership of the patents and other intellectual property.
If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates.
Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.
We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time-consuming and unsuccessful.

Related Party Transactions

David Schamis, expected Pubco CEO and director, is a manager of Rorschach Advisors LLC (Advisor).
Pubco will issue Advisor Shares (5% of outstanding Pubco Common Stock) and Advisor Warrants (15% of fully diluted Pubco Common Stock) to the Advisor.
Pubco and Advisor will enter into an Advisor Rights Agreement (director nomination and information rights) and a Strategic Advisor Agreement (technical advisory services for digital asset ecosystem).
The Advisory Agreement provides for Advisor to receive equity grants (5% shares, 15% warrants) in future equity/equity-linked financings.
Chardan Capital Markets LLC acted as Rorschach's exclusive M&A advisor for the Business Combination, entitled to a $4.0 million fee (Rorschach Fee), payable in cash or equity.
Chardan acted as Sonnet's and Rorschach's exclusive advisor for the Closing PIPE, entitled to a fee up to 7.0% of gross proceeds (Sonnet Fee), payable in cash or equity.
Chardan served as underwriter/placement agent for Sonnet's public/private offerings in November 2024, October 2023, February 2023, December 2024, and June 2023.
Sonnet entered into a committed equity facility with Chardan in May 2024 for up to $25.0 million.
Chardan is expected to own approximately 2,182,240 shares of Common Stock as payment of the Rorschach Fee and Sonnet Fee.
Dr. Richard Kenney (Sonnet's Chief Medical Officer) participated in a July 2025 private placement of convertible notes ($0.2 million principal) and warrants.
Raghu Rao (Sonnet's current Interim CEO and director) purchased 1,953 shares and warrants in an October 2023 public offering.
Pankaj Mohan (Sonnet's former CEO) purchased 4,296 shares and warrants in an October 2023 public offering.
Sonnet has entered into indemnification agreements with each of its current directors and executive officers.

Stakeholder Impact

Shareholders: Significant dilution from equity facility and business combination, potential for volatility in stock price due to HYPE token strategy, potential for long-term value appreciation if HYPE strategy is successful, but also risk of substantial losses. Sonnet shareholders will receive CVRs, but payment is uncertain.
Employees: Uncertainty about roles post-merger, potential for disruption, but also new opportunities within the combined entity.
Customers/Patients (Sonnet's biotech business): Continued development of product candidates like SON-1010, potential for new therapies, but also risks of delays or failures in clinical trials.
Creditors: Potential for additional debt financing, HYPE holdings may serve as collateral, but also risks related to HYPE volatility and regulatory uncertainty affecting ability to meet obligations.
Regulatory Bodies: Increased scrutiny due to digital asset strategy, evolving regulatory landscape, and compliance requirements.

Next Steps

Closing of the Business Combination between Hyperliquid Strategies Inc., Sonnet BioTherapeutics Holdings, Inc., and Rorschach I LLC.
Filing of an amended and restated Charter to increase authorized common stock.
Initial listing of Pubco Common Stock on the Nasdaq Capital Market under the symbol PURR.
Pubco to allocate substantially all cash proceeds from the Closing PIPE (excluding $15-30 million reserve) to acquire HYPE tokens.
Launch of HYPE staking program with third-party providers.
Ongoing monitoring of market conditions for opportunities to raise additional capital for HYPE token accumulation.
Optimization of staking rewards by diversifying across 3-5 validators.
Reinvestment of staking rewards into additional HYPE token accumulation.
Exploration of opportunistic M&A transactions involving HYPE-aligned businesses.
Sonnet to continue development of SON-1010.
Alkem to initiate Phase 2 clinical trial for SON-080 in DPN.
IND submission and first patient dosed for SON-1210 in H2 calendar year 2025.
Expected topline efficacy data for SON-1010 in STS with trabectedin and for PROC combo with atezolizumab in H2 calendar year 2025.
Negotiation of 'Give Back Option' terms with New Life for SON-080.

Key Dates

Date	Description
2009	Genesis block on the Bitcoin blockchain mined.
2012-07-23	Discovery Collaboration Agreement between XOMA (US) LLC and Oncobiologics, Inc. (Sonnet's predecessor).
2015-04-06	Sonnet BioTherapeutics, Inc. (Prior Sonnet) incorporated as a New Jersey corporation.
2015-08-28	Relief (Sonnet subsidiary) signed License Agreement with Ares Trading (ARES).
2018-02-20	PCT patent application WO/2018/151868 (PCT/US2018/00085) filed.
2019-01	Sonnet entered into Frame Services and License Agreement with Sartorius Stedim Cellca GMBH (Cellca).
2019-05-07	Amendment of Discovery Collaboration Agreement between XOMA (US) LLC and Sonnet BioTherapeutics, Inc.
2020-04-01	Sonnet completed merger with Chanticleer Holdings, Inc., changing its name to Sonnet BioTherapeutics Holdings, Inc. and acquiring Relief Therapeutics SA.
2020-08	Sonnet received $0.5 million upfront cash payment from New Life upon executing a letter of intent.
2020-09-17	International registrational approval with WIPO for Sonnet BioTherapeutics and FHAB marks.
2020-11-30	Sonnet BioTherapeutics mark published by EUIPO.
2020-12-06	FHAB mark published by EUIPO.
2021-05-11	US provisional application directed to Antigen/Albumin Binding Domain Conjugates re-filed as US 63/187,278 (later abandoned).
2021-05	Sonnet entered into License Agreement (New Life Agreement) with New Life Therapeutics Pte., Ltd.
2021-06	Sonnet received U.S. patent for FHAB technology. Sonnet received $0.5 million upfront cash payment from New Life upon execution of the New Life Agreement.
2021-06-11	First Amendment to New Life Agreement.
2021-07-07	Second Amendment to New Life Agreement.
2021-09	Sonnet created wholly-owned Australian subsidiary, SonnetBio Pty Ltd.
2021-09-22	US provisional application directed to anti-IL6-FHAB fusion proteins re-filed as US 63/245,702 (later abandoned).
2021-10	Amendment to ARES License Agreement and Settlement effective.
2021-10	Hackers exploited a flaw in Coinbase account recovery process.
2021-12-07	US provisional application directed to Antibody-Based Drug Conjugates filed as Application no. 63/286,996 (later abandoned).
2021-12	Sonnet entered into Research and Development Agreement (Navigo Agreement) with Navigo Proteins GmbH.
2022-02	SEC issued cease-and-desist order under Investment Company Act to BlockFi Lending LLC.
2022-03	FDA cleared Sonnet's Investigational New Drug (IND) application for SON-1010.
2022-03	Sonnet entered into Material Transfer and License Agreement (ProteoNic Agreement) with ProteoNic B.V.
2022-04	Sonnet initiated U.S. clinical trial (SB101) for SON-1010.
2022-05-27	US provisional patent application directed to IL-12-Albumin-Binding Domain Fusion Protein Formulations and Methods of Use Thereof filed as Application no. 63/346,368.
2022-06-03	US provisional application 'Method of Treating Age-Related Frailty with Interleukin-6' converted to PCT application (PCT/US22/32215).
2022-06-08	Canadian Intellectual Property Office granted protection to Sonnet BioTherapeutics mark.
2022-07	Sonnet initiated Australian clinical study (SB102) of SON-1010 in healthy volunteers.
2022-10	Sonnet initiated ex-U.S. Phase 1b/2a study with SON-080 in CIPN (SB211).
2022-10	Sonnet entered collaboration agreement with Janssen Biotech, Inc. for in vitro and in vivo efficacy evaluation of SON-1010, SON-1210, and SON-1410.
2022-11	Hackers exploited weaknesses in FTX Trading digital asset exchange.
2022-11-16	18-month opposition period began for FHAB mark in Canada.
2022-12-21	Russian Patent No. 2786444 issued for FHAB Fusion Proteins.
2022-12-23	Japanese Patent No. 7200138 issued for FHAB Fusion Proteins.
2023-01	Sonnet announced collaboration agreement with Roche for clinical evaluation of SON-1010 with atezolizumab.
2023-02	Sonnet announced successful completion of two IND-enabling toxicology studies with SON-1210 in NHPs.
2023-03-14	US provisional patent application directed to Methods of Making Recombinant IL-12 Albumin Binding Domain Fusion Proteins filed as Application no. 63/490,202.
2023-05-26	US provisional patent application 'IL-12-Albumin-Binding Domain Fusion Protein Formulations and Methods of Use Thereof' converted to PCT application (PCT/US2023/067566).
2023-06	SEC filed complaints against Binance and Coinbase, Inc.
2023-06	European Union adopted Markets in Crypto Assets Regulation. United Kingdom adopted and implemented Financial Services and Markets Act 2023.
2023-08	FDA accepted IND for SB221.
2023-09-29	US provisional patent application 'Low Dose IL-6 Formulations and Methods of Use Thereof' converted to PCT application (PCT/US2023/075593).
2023-09	Sonnet announced completion of two independent in vivo proof-of-concept (POC) studies for biodistribution of interleukin-FHAB molecules.
2023-10-03	New Zealand Patent No. 756674 issued for FHAB Fusion Proteins.
2023-10-26	Sonnet closed a public offering of common stock and warrants.
2023-10-27	Closing date for Sonnet's October 2023 public offering.
2023-11	Binance Holdings Ltd. and its then CEO reached settlement with U.S. Department of Justice, CFTC, OFAC, and FinCEN. SEC filed complaint against Payward Inc. and Payward Ventures Inc. (Kraken).
2023-11-01	US provisional patent application 'Methods for the Treatment of Cancer with Recombinant IL-12 Albumin Binding Domain Fusion Proteins' converted to PCT application (PCT/US2023/078366).
2023-11-30	US National Stage application (U.S. Pat. Appl. No. 18/566,029) for 'Method of Treating Age-Related Frailty with Interleukin-6' filed.
2023-12-20	Preclinical data on SON-1210 published.
2023-12-29	US provisional patent application directed to Interleukin 18 (IL-18) Variants and Fusion Proteins Comprising Same filed as Application no. 63/616,148.
2024-01	Sonnet terminated ProteoNic Agreement.
2024-02	Data from SB102 study published.
2024-03-06	US provisional patent application directed to Methods For The Treatment Of Diabetes-Associated Autonomic Neuropathy filed as Application no. 63/561,924.
2024-03-13	US provisional patent application 'Methods of Making Recombinant IL-12 Albumin Binding Domain Fusion Proteins' converted to PCT application (PCT/US2024/19798).
2024-03	DSMB reviewed preliminary blinded safety data for SB211 study and cleared it to proceed to Phase 2.
2024-04-12	US provisional patent application directed to Methods of Making Recombinant IL-12/IL-15 Albumin Binding Domain Fusion Proteins filed as Application no. 63/633,641.
2024-04-26	Chinese Patent No. ZL201880016019.1 issued for FHAB Fusion Proteins.
2024-05-02	Sonnet entered into ChEF Purchase Agreement and Registration Rights Agreement with Chardan.
2024-06-11	U.S. Patent and Trademark Office granted patent No. 12,006,361, titled, Albumin Binding Domain Fusion Proteins, covering composition of matter for SON-1210.
2024-06-19	Sonnet entered into inducement offer letter agreements with warrant holders.
2024-06-21	Warrant Inducement Offering closed.
2024-06-10	US provisional patent application directed to Interleukin 18 (IL-18) Variants and Fusion Proteins Comprising Same filed as Application no. 63/658,322.
2024-07	Data from SB211 study announced, showing safety, tolerability and preliminary evidence of improvement in symptoms.
2024-08-05	Sonnet received Nasdaq delisting notice for bid price non-compliance.
2024-08-19	Sonnet entered into Master Clinical Collaboration Agreement (SOC Agreement) with Sarcoma Oncology Center.
2024-08-28	Nasdaq granted Sonnet an exception until October 15, 2024, to regain compliance with minimum bid price requirement.
2024-09-12	Sonnet stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split.
2024-09-18	Sonnet announced completion of dose-escalation enrollment in Phase 1 SB101 clinical trial.
2024-09-25	Sonnet filed Certificate of Amendment for a one-for-eight (1:8) reverse stock split, effective September 30, 2024.
2024-09-30	Effective date of Sonnet's 1-for-8 reverse stock split.
2024-10-08	Sonnet signed licensing agreement with Alkem Laboratories Limited for SON-080.
2024-10-16	Sonnet received letter from Nasdaq stating it regained compliance with the Bid Price Requirement.
2024-10-17	Average of high and low prices of Sonnet common stock on Nasdaq used for fee calculation ($3.635).
2024-10-21	US provisional patent application directed to Antibody-Based Drug Conjugates filed as Application no. 63/709,765.
2024-11-05	U.S. Patent No. 12134635 issued for Interleukin 18 (IL-18) Variants and Fusion Proteins Comprising Same.
2024-11-06	Sonnet entered into an underwriting agreement with Chardan for a public offering.
2024-11-07	Sonnet's public offering closed.
2024-11-29	HYPE Token Generation Event via airdrop.
2024-12-02	New Life provided written notice to Sonnet of its intention to exercise its Give Back Option for SON-080.
2024-12-09	Sonnet entered into a definitive agreement for a registered direct offering and concurrent private placement.
2024-12-10	Sonnet's registered direct and concurrent private placement offerings closed.
2024-12	Sonnet announced topline safety data from SB101 and completion of dose escalation.
2025-01	Sonnet announced expansion of Phase 1 SB101 clinical study to add a new cohort.
2025-02	Complaint against Coinbase dismissed. Complaint against Payward Inc. and Payward Ventures Inc. dismissed with prejudice in March 2025.
2025-03-26	Successful completion of the first safety review of the SB101 expansion cohort with trabectedin.
2025-04-01	Raghu Rao replaced Dr. Mohan as Sonnet's Interim Chief Executive Officer.
2025-04	State of Oregon brought civil enforcement action against Coinbase.
2025-04-04	Update on safety in SB221 trial released after MTD established at 1200 ng/kg.
2025-05	SEC issued statement on staking activities. Complaint against Binance dismissed.
2025-05	Alkem paid $0.5 million upfront payment to Sonnet.
2025-05	Sonnet entered into Material Transfer and License Agreement (ProteoNic Agreement) with ProteoNic B.V.
2025-06-13	Rorschach I LLC incorporated.
2025-06-30	Sonnet completed Bridge Financing of $2.0 million convertible notes.
2025-07-02	Hyperliquid Strategies Inc. (Pubco) incorporated. Rorschach acquired all issued and outstanding stock in Hyperliquid Strategies Inc for no consideration.
2025-07-08	Pubco issued 100 shares of common stock to Rorschach I LLC for no consideration.
2025-07-09	Sonnet issued 120,000 RSUs.
2025-07-11	Business Combination Agreement dated between Sonnet, Rorschach, Pubco, TBS Merger Sub Inc., and Rorschach Merger Sub, LLC.
2025-07	Sonnet completed a private placement of zero-interest convertible notes, raising $2.0 million. Sonnet closed a $5.5 million PIPE to accredited investors. Holders exercised outstanding warrants to purchase 3,421,624 shares of common stock, resulting in gross proceeds of $10.5 million.
2025-07-29	Hyperliquid's API servers experienced a significant spike in traffic.
2025-07-30	President Trump's working group submitted a report with regulatory and legislative proposals for digital assets.
2025-08-04	Sonnet announced a second PR at the highest dose in PROC and the addition of a seventh dose level cohort for SB221.
2025-08-13	Date unaudited interim consolidated financial statements were available to be issued.
2025-08-26	Hyperliquid announced increase of Assistance Fund's fee share from 97% to 99%.
2025-09-30	As of date for Pubco's executive officers and directors ages.
2026-07-08	Vesting date for 120,000 RSUs issued by Sonnet on July 9, 2025.
2026-07-11	Outside Date for Business Combination.
2027-05-16	Expiration date of the ChEF Purchase Agreement.
2027-09-30	Expiration of Medicare payment reductions of 2% per fiscal year.
2028-02	InvivoGen Agreement extended through this month.
2030-09-17	Renewal date for Sonnet BioTherapeutics and FHAB marks.
2030	Federal net operating losses begin to expire.
2032	State research and development tax credit carryforwards begin to expire.
2035	Federal research and development tax credit carryforwards begin to expire.
2038-02-20	Estimated expiration date for Japanese Patent No. 7200138, Russian Patent No. 2786444, Chinese Patent No. ZL201880016019.1 and New Zealand Patent No. 756674.
2039-03-26	Estimated expiration date for U.S. Patent No. 11,028,166.
2039	State net operating losses begin to expire.

Recommendation

hold

The filing outlines a significant capital raise potential through the ChEF and a bold strategic shift into digital asset treasury management, which could offer substantial upside if successful. However, the inherent volatility and regulatory uncertainty of HYPE tokens, coupled with the significant dilution for existing shareholders and the ongoing financial challenges of the biotech subsidiary, present considerable risks. A 'Hold' recommendation is appropriate as the long-term potential is high but speculative, and current investors should monitor the execution of the HYPE treasury strategy and regulatory developments closely before making further investment decisions. New investors might consider waiting for more clarity on the HYPE token strategy's initial performance and regulatory landscape.

Keywords

Committed Equity Facility, ChEF, Hyperliquid Strategies, Chardan Capital Markets, SEC Filing, S-1, Equity Financing, HYPE Token, Cryptocurrency, Blockchain, Digital Assets, Sonnet BioTherapeutics, Business Combination, Dilution, Risk Management, Staking, Biotech, Oncology, IL-12, IL-6, IL-15, FHAB Technology, Nasdaq Listing, Corporate Governance

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.